Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

A Safe GDNF and GDNF/BDNF Controlled Delivery System Improves Migration in Human Retinal Pigment Epithelial Cells and Survival in Retinal Ganglion Cells: Potential Usefulness in Degenerative Retinal Pathologies

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Publication Information:
      MDPI
    • Publication Date:
      2021
    • Collection:
      Universidad Complutense de Madrid (UCM): E-Prints Complutense
    • Abstract:
      We assessed the sustained delivery effect of poly (lactic-co-glycolic) acid (PLGA)/vitamin E (VitE) microspheres (MSs) loaded with glial cell-derived neurotrophic factor (GDNF) alone (GDNF-MSs) or combined with brain-derived neurotrophic factor (BDNF; GDNF/BDNF-MSs) on migration of the human adult retinal pigment epithelial cell-line-19 (ARPE-19) cells, primate choroidal endothelial (RF/6A) cells, and the survival of isolated mouse retinal ganglion cells (RGCs). The morphology of the MSs, particle size, and encapsulation efficiencies of the active substances were evaluated. In vitro release, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell viability, terminal deoxynucleotidyl transferase (TdT) deoxyuridine dUTP nick-end labelling (TUNEL) apoptosis, functional wound healing migration (ARPE-19; migration), and (RF/6A; angiogenesis) assays were conducted. The safety of MS intravitreal injection was assessed using hematoxylin and eosin, neuronal nuclei (NeuN) immunolabeling, and TUNEL assays, and RGC in vitro survival was analyzed. MSs delivered GDNF and co-delivered GDNF/BDNF in a sustained manner over 77 days. The BDNF/GDNF combination increased RPE cell migration, whereas no effect was observed on RF/6A. MSs did not alter cell viability, apoptosis was absent in vitro, and RGCs survived in vitro for seven weeks. In mice, retinal toxicity and apoptosis was absent in histologic sections. This delivery strategy could be useful as a potential co-therapy in retinal degenerations and glaucoma, in line with future personalized long-term intravitreal treatment as different amounts (doses) of microparticles can be administered according to patients’ needs. ; Depto. de Farmacia Galénica y Tecnología Alimentaria ; Fac. de Farmacia ; TRUE ; Spanish Ministry of Economy, Industry and Competitiveness (MAT2017-83858-C2-1-R) ; Complutense Research Group UCM 920415, Innovation, Therapy and Pharmaceutical Development in Ophthalmology (InnOftal), Fundación Jesús Gangoiti Barrera ; Instituto de Salud Carlos III ...
    • File Description:
      application/pdf
    • ISSN:
      1424-8247
    • Relation:
      https://www.mdpi.com/journal/pharmaceuticals; https://hdl.handle.net/20.500.14352/7424
    • Accession Number:
      10.3390/ph14010050
    • Online Access:
      https://hdl.handle.net/20.500.14352/7424
      https://doi.org/10.3390/ph14010050
      https://www.mdpi.com/journal/pharmaceuticals
    • Rights:
      Atribución 3.0 España ; open access ; https://creativecommons.org/licenses/by/3.0/es/
    • Accession Number:
      edsbas.85EA22FF